Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Comparison between regimes of rifampicin-isoniazid administered daily and administered twice a week (initial results of a comparative study conducted in 4 medical services of the Parisian region)].

Authors: Meredith Milstein; Leonid Lecca; Charles Peloquin; Denis Mitchison; Kwonjune Seung; Marcello Pagano; David Coleman; Elna Osso; Julia Coit; Dante Elmo Vargas Vasquez; Epifanio Sanchez Garavito; Roger Calderon; Carmen Contreras; Geraint Davies; Carole D Mitnick
Journal: BMC Infect Dis Date: 2016-08-27 Impact factor: 3.090

7. Intracellular PD Modelling (PD_i) for the Prediction of Clinical Activity of Increased Rifampicin Dosing.

Authors: Ghaith Aljayyoussi; Samantha Donnellan; Stephen A Ward; Giancarlo A Biagini
Journal: Pharmaceutics Date: 2019-06-13 Impact factor: 6.321

7 in total

[Comparison between regimes of rifampicin-isoniazid administered daily and administered twice a week (initial results of a comparative study conducted in 4 medical services of the Parisian region)].

Review 1. Tuberculosis pharmacotherapy: strategies to optimize patient care.

2. Intermittent treatment regimens in pulmonary tuberculosis.

3. Tuberculous infection.

4. Intermittent chemotherapy in pulmonary tuberculosis--current aspects.

Review 5. Antituberculosis therapy for 2012 and beyond.

6. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.

7. Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing.

7. Intracellular PD Modelling (PD_i) for the Prediction of Clinical Activity of Increased Rifampicin Dosing.